Check-CapSTU:7CC +0.88%25 EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus rates STU:7CC with a GF Score™ of 25/100. The stock has 2 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Check-Cap ranks worse than 490195.59% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Check-Cap's EBITDA for the
six
months ended in Dec. 2025 was €4.83 Mil. Check-Cap's Revenue for the
six
months ended in Dec. 2025 was €0.00 Mil. Therefore, Check-Cap's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.
Check-Cap (STU:7CC) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Check-Cap EBITDA Margin % Related Terms
Check-Cap EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Check-Cap's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:7CC vs XWEL, NDRA, NOTV: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Check-Cap's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Check-Cap EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Check-Cap's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Check-Cap's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Check-Cap (STU:7CC) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Check-Cap and its competitors. According to the industry distribution chart, Check-Cap ranks #999999 out of 204 companies in the Medical Diagnostics & Research industry.
Is Check-Cap's EBITDA Margin % too high?
Check-Cap's current EBITDA Margin % is 0.00%. Based on the distribution chart, Check-Cap ranks #999999 out of 204 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Check-Cap has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Check-Cap's EBITDA Margin % compare to XWEL and NDRA?
According to the Medical Diagnostics & Research industry distribution chart, Check-Cap ranks #999999 out of 204 companies for EBITDA Margin %. This places Check-Cap in the lower half of its industry. The industry median EBITDA Margin % is 5.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Check-Cap and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Check-Cap's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Check-Cap stock overvalued right now?
Check-Cap (STU:7CC) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Check-Cap's overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Check-Cap (STU:7CC), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.
25GF Score
Get the complete analysis for STU:7CC
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7CC has been successfully added to your 
